Log in

NYSE:IMVIMV Stock Price, Forecast & News

$5.11
+0.04 (+0.79 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.95
Now: $5.11
$5.15
50-Day Range
$2.78
MA: $3.96
$5.95
52-Week Range
$1.35
Now: $5.11
$6.82
Volume683,831 shs
Average Volume875,827 shs
Market Capitalization$315.29 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
IMV, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm's patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
CUSIPN/A
CIKN/A
WebN/A
Phone(902) 492-1819

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$315.29 million
Next Earnings Date8/12/2020 (Confirmed)
OptionableNot Optionable
$5.11
+0.04 (+0.79 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMV News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IMV (NYSE:IMV) Frequently Asked Questions

How has IMV's stock been impacted by COVID-19 (Coronavirus)?

IMV's stock was trading at $2.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IMV shares have increased by 114.7% and is now trading at $5.11.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of IMV?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IMV
.

When is IMV's next earnings date?

IMV is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for IMV
.

How were IMV's earnings last quarter?

Imv Inc (NYSE:IMV) announced its quarterly earnings results on Friday, May, 15th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.03. The firm earned $0.05 million during the quarter, compared to analysts' expectations of $0.04 million.
View IMV's earnings history
.

What price target have analysts set for IMV?

8 Wall Street analysts have issued twelve-month target prices for IMV's shares. Their forecasts range from $3.00 to $13.00. On average, they expect IMV's share price to reach $8.14 in the next twelve months. This suggests a possible upside of 59.4% from the stock's current price.
View analysts' price targets for IMV
.

Has IMV been receiving favorable news coverage?

Press coverage about IMV stock has been trending negative recently, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. IMV earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about IMV
.

Who are some of IMV's key competitors?

What other stocks do shareholders of IMV own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IMV investors own include Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), Gilead Sciences (GILD), Nokia Oyj (NOK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Vaxart (VXRT), ADMA Biologics (ADMA) and Amplify Energy (AMPY).

Who are IMV's key executives?

IMV's management team includes the following people:
  • Frederic Ors, CEO, Director & Chief Business Officer
  • Pierre Labbé, Chief Financial Officer
  • Gabriela Nicola Rosu, Chief Medical Officer
  • Marianne Stanford, Vice President-Research
  • Joseph Sullivan, Senior Vice President-Business Development

What is IMV's stock symbol?

IMV trades on the New York Stock Exchange (NYSE) under the ticker symbol "IMV."

Who are IMV's major shareholders?

IMV's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Creative Planning (0.08%) and Vident Investment Advisory LLC (0.02%).

Which institutional investors are buying IMV stock?

IMV stock was bought by a variety of institutional investors in the last quarter, including Creative Planning, and Vident Investment Advisory LLC.

How do I buy shares of IMV?

Shares of IMV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IMV's stock price today?

One share of IMV stock can currently be purchased for approximately $5.11.

How big of a company is IMV?

IMV has a market capitalization of $315.29 million.

How can I contact IMV?

The company can be reached via phone at (902) 492-1819.

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.